| Literature DB >> 29710789 |
Elin M Hård Af Segerstad1, Hye-Seung Lee2, Carin Andrén Aronsson3, Jimin Yang4, Ulla Uusitalo5, Ingegerd Sjöholm6, Marilyn Rayner7, Kalle Kurppa8, Suvi M Virtanen9, Jill M Norris10, Daniel Agardh11.
Abstract
Milk powder and gluten are common components in Swedish infants' diets. Whereas large intakes of gluten early in life increases the risk of celiac disease in genetically at-risk Swedish children, no study has yet evaluated if intake of milk powder by 2 years of age is associated with celiac disease. A 1-to-3 nested case-control study, comprised of 207 celiac disease children and 621 controls matched for sex, birth year, and HLA genotype, was performed on a birth cohort of HLA-DR3-DQ2 and/or DR4-DQ8-positive children. Subjects were screened annually for celiac disease using tissue transglutaminase autoantibodies (tTGA). Three-day food records estimated the mean intake of milk powder at ages 6 months, 9 months, 12 months, 18 months, and 24 months. Conditional logistic regression calculated odds ratios (OR) at last intake prior to seroconversion of tTGA positivity, and for each time-point respectively and adjusted for having a first-degree relative with celiac disease and gluten intake. Intake of milk powder prior to seroconversion of tTGA positivity was not associated with celiac disease (OR = 1.00; 95% CI = 0.99, 1.03; p = 0.763). In conclusion, intake of milk powder in early childhood is not associated with celiac disease in genetically susceptible children.Entities:
Keywords: HLA; Sweden; commercial infant foods; formula; gluten; infant feeding; milk powder
Mesh:
Substances:
Year: 2018 PMID: 29710789 PMCID: PMC5986430 DOI: 10.3390/nu10050550
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Flowchart of the study population.
Characteristics of the identified cases with celiac disease in the Swedish TEDDY birth cohort used as matching factors in a nested 1-3 case-control study.
| Matching Variable | Cases N = 207 (%) |
|---|---|
| Sex | |
| - Female | 131 (63.3) |
| - Male | 76 (36.7) |
| Birth year | |
| - 2004 | 11 (5.3) |
| - 2005 | 39 (18.8) |
| - 2006 | 28 (13.5) |
| - 2007 | 41 (19.8) |
| - 2008 | 37 (17.9) |
| - 2009 | 46 (22.2) |
| - 2010 | 5 (2.4) |
| HLA-genotype | |
| - DQ2/DQ8 | 64 (30.9) |
| - DQ8/DQ8 | 35 (16.9) |
| - DQ2/DQ2 | 100 (48.3) |
| - Other | 8 (3.9) |
Figure 2Body weight at clinic visit (a) and assessed daily mean intake of energy (kcal) (b), mean daily intake of milk powder (gram per day) from 3-day food records in cases with celiac disease and matched, healthy controls (1:3) (c). For breastfed subjects, energy intake was estimated using assessed energy requirement and subtracting energy intake from other reported food. Controls were matched to cases by gender, HLA genotype and birth year.
Comparison of mean daily intake of milk powder (grams per day and grams per kilo bodyweight) in cases with celiac disease and matched, healthy controls (1:3), and risk of celiac disease analyzed with conditional logistic regression expressed as odds ratio (OR) after adjusting for having a first-degree relative with celiac disease and for gluten intake at the given time point. Controls were matched to cases by gender, HLA genotype and birth year.
| Time point | Number of cases analyzed | Number of cases missing intake | Milk powder intake (g/day) | Milk powder intake (g/kg/day) | ||
|---|---|---|---|---|---|---|
| OR (CI 95%) | OR (CI 95%) | |||||
| Last intake 1 | 207 | 0 | 1.0 (0.99–1.01) | 0.937 | 0.99 (0.87–1.13) | 0.861 |
| Total intake 2 | 207 | 0 | 1.0 (1.0–1.00) | 0.662 | 1.0 (0.98–1.03) | 0.763 |
| Intake at | ||||||
| 3 months | 207 | 0 | 0.99 (0.97–1.01) | 0.159 | 0.92 (0.83–1.02) | 0.125 |
| 6 months | 202 | 5 | 1.0 (0.99–1.02) | 0.643 | 1.02 (0.91–1.13) | 0.788 |
| 9 months | 198 | 9 | 1.01 (1.0–1.02) | 0.069 | 1.09 (0.99–1.19) | 0.072 |
| 12 months | 192 | 9 | 1.01 (1.0–1.02) | 0.181 | 1.08 (0.96–1.21) | 0.184 |
| 18 months | 146 | 21 | 1.0 (0.98–1.02) | 0.983 | 1.01 (0.84–1.21) | 0.923 |
| 24 months | 103 | 19 | 0.99 (0.97–1.01) | 0.202 | 0.88 (0.69–1.12) | 0.301 |
1 Last reported intake at the visit prior to seroconversion of tTGA; 2 Sum of all reported intakes prior to seroconversion of tTGA